Pulmatrix Inc
PULM5.440USD
+0.050+0.93%
Horário de mercado （ET）Cotações atrasadas em 15 min
19.87MValor de mercado
PerdaP/L TTM
Mais detalhes de Pulmatrix Inc Empresa
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Informações da empresa
Código da empresaPULM
Nome da EmpresaPulmatrix Inc
Data de listagemMar 21, 2014
CEOMr. Peter B. Ludlum
Número de funcionários2
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 21
Endereço945 Concord Street
CidadeFRAMINGHAM
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01701
Telefone18883554440
Sitehttps://www.pulmatrix.com/
Código da empresaPULM
Data de listagemMar 21, 2014
CEOMr. Peter B. Ludlum
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
7.83K
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Independent Director
Independent Director
4.16K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
Independent Director
Independent Director
4.16K
--
Mr. Anand Varadan
Mr. Anand Varadan
Independent Director
Independent Director
3.32K
--
Mr. Timothy McCarthy
Mr. Timothy McCarthy
Investor Relations
Investor Relations
--
--
Mr. Peter B. Ludlum
Mr. Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Interim Chief Executive Officer and Interim Chief Financial Officer
--
--
Dr. Richard Batycky, Ph.D.
Dr. Richard Batycky, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
7.83K
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Independent Director
Independent Director
4.16K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
Independent Director
Independent Director
4.16K
--
Mr. Anand Varadan
Mr. Anand Varadan
Independent Director
Independent Director
3.32K
--
Mr. Timothy McCarthy
Mr. Timothy McCarthy
Investor Relations
Investor Relations
--
--
Mr. Peter B. Ludlum
Mr. Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Interim Chief Executive Officer and Interim Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 29 de mai
Atualizado em: qui, 29 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Renaissance Technologies LLC
2.98%
BlackRock Institutional Trust Company, N.A.
1.50%
SBI Securities Co., Ltd.
1.43%
The Vanguard Group, Inc.
1.16%
Geode Capital Management, L.L.C.
1.11%
Other
91.81%
Investidores
Investidores
Proporção
Renaissance Technologies LLC
2.98%
BlackRock Institutional Trust Company, N.A.
1.50%
SBI Securities Co., Ltd.
1.43%
The Vanguard Group, Inc.
1.16%
Geode Capital Management, L.L.C.
1.11%
Other
91.81%
Tipos de investidores
Investidores
Proporção
Hedge Fund
3.00%
Investment Advisor/Hedge Fund
2.88%
Investment Advisor
1.53%
Research Firm
1.43%
Individual Investor
0.66%
Other
90.49%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
32
347.44K
9.51%
-94.22K
2025Q1
34
346.08K
9.48%
-117.47K
2024Q4
30
329.25K
9.01%
-61.75K
2024Q3
31
276.56K
7.57%
-108.94K
2024Q2
31
263.58K
7.22%
-1.04M
2024Q1
33
261.48K
7.16%
-1.04M
2023Q4
39
316.17K
8.66%
-1.16M
2023Q3
44
516.38K
14.50%
-1.18M
2023Q2
48
580.98K
16.42%
-1.18M
2023Q1
54
668.56K
18.82%
-1.15M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Renaissance Technologies LLC
108.92K
2.98%
-200.00
-0.18%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
54.90K
1.5%
--
--
Mar 31, 2025
SBI Securities Co., Ltd.
52.36K
1.43%
-13.83K
-20.90%
Mar 31, 2025
The Vanguard Group, Inc.
42.40K
1.16%
+7.32K
+20.87%
Mar 31, 2025
Geode Capital Management, L.L.C.
40.37K
1.11%
+3.50K
+9.48%
Mar 31, 2025
State Street Global Advisors (US)
13.95K
0.38%
--
--
Mar 31, 2025
Higgins (Michael J)
7.83K
0.21%
--
--
May 01, 2025
Dimensional Fund Advisors, L.P.
6.25K
0.17%
+1.36K
+27.72%
May 31, 2025
Batycky (Richard P. Ph.D.)
4.69K
0.13%
--
--
May 01, 2025
Bazemore (Todd M)
4.16K
0.11%
--
--
May 01, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Data
Tipo
Proporção
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
